Drug Trial Radar · NCT07001748
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
148
Planned (sponsor's estimate)
Start
Oct 24, 2025
Primary completion
May 30, 2030
Study completion May 30, 2031
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will administering paclitaxel chemotherapy directly into your abdominal cavity, in addition to chemotherapy given through a vein in your arm help you live longer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your gastric cancer. The usual approach is defined as care most people get for gastric cancer. If you decide to take part in this study, you will first receive a surgical procedure called a diagnostic laparoscopy. This will help the study doctors learn more about your gastric cancer. Laparoscopy is a minimally invasive surgery for which you will be placed under general anesthesia. Then the surgeon will make small incisions (5mm) on your belly through which a camera and thin instruments are introduced to evaluate the abdomen. This procedure takes about 1 hour to complete. Your study group will be assigned during the surgery. The study groups are described further in the 'What are the study groups?' section below. If you are placed into the study group 1, you will not have an intraperitoneal port (a small device which is placed under the skin and fat of your upper abdomen and a tube that is placed into the abdomen). If you are placed into the study group 2, you will have an intraperitoneal port placed. The reason is that in addition to standard chemotherapy, which is given through a vein in your arm, this port will be used to deliver the medication paclitaxel directly inside your abdomen when you are ready to start study treatment. It is important to know that you will not know your study group until after the surgery is over. This is because information that is learned during the surgery will help determine which study group you are put in. Once you have fully healed from this surgery, you will start study treatment. Depending on which study group you are assigned, you will either receive a standard chemotherapy regimen (the regimen will be chosen by you and your doctor) if you are in study group 1, or paclitaxel through a tube in your belly plus chemotherapy given through a vein in your arm if you are in study group 2. All participants will get treatment for three (3) months after which you will undergo reevaluation. If the disease is under control or responding to treatment, you may continue the assigned treatment until your disease gets worse, the side effects become too severe, or you may be offered a surgical procedure to remove the cancer if the amount of disease is low and can be completely removed as determined by a surgeon. There is a very small chance that during the laparoscopy surgical procedure, the doctor might find something called "intra-abdominal adhesions". These are areas where the stomach has healed previously and created scar tissue. If this scar tissue prevents the surgeon from being able to place a port in the correct area, you would be ineligible to receive the study treatment. If this happens, you may still receive standard of care therapy after your surgery, but you will not be able to continue on the study. If you have more questions about this, you can ask your surgeon or the study team to help. After you finish your study treatment, your doctor or study team will watch you for side effects. They will continue to follow your condition every three (3) months during the first two (2) years, then every six (6) months until year 5. You may be reevaluated with Chest/Abdomen/Pelvis scans every three-six (3-6) months for up to five (5) years if decided by your doctor.
Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Peritoneal Carcinomatosis
Interventions
Standard of Care ChemotherapyDrug
The most common regimens are FOLFOX, CAPOX, FLOT, CF, and CX. Other local institutional standard of care regimens as well as targeted agents for gastric/GEJ adenocarcinoma are allowed.
Biospecimen CollectionProcedure
Plasma is to be submitted at baseline and every three months for the first year or until progression, whichever comes first. For patients who have progression, their last plasma sample should be at time of progression.
Computed TomographyProcedure
Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.
Diagnostic LaparoscopyProcedure
After induction of general anesthesia, administration of preoperative antibiotics and placement of appropriate laparoscopic ports, peritoneal lavage will be performed by instillation of 200 ml of normal saline in the left upper quadrant and allowed to dwell for 5 minutes after which it will be aspirated for cytology. Extent of peritoneal disease burden will be ascertained as per the Peritoneal Cancer Index (PCI) scoring system as outlined in Appendix V.
Intraperitoneal Port PlacementProcedure
Patients assigned to Arm B will undergo placement of indwelling tunneled intraperitoneal port with Teflon cuff following Step 1 randomization and during the diagnostic laparoscopy procedure.
Magnetic Resonance ImagingProcedure
Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.
Intraperitoneal PaclitaxelDrug
Patients on Arm B will start systemic therapy + intraperitoneal paclitaxel as early as the day after Step 1 randomization and must start within 30 calendar days (including holidays) after Step 1 randomization as per the schedule shown in the table below. Therapy will be administered on Days 1 and 8 of a 21-day cycle for 4 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (Phase II)Time frame: From randomization to progression or death without documentation of progression, assessed up to 5 years.
- Overall survival (Phase III)Time frame: From randomization to the date of death, of any cause, assessed up to 5 years
Locations
78 sites in 1 country. Site status is shown where the registry gives one.
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Fairfield
Fairfield, Connecticut · Recruiting
Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Yale-New Haven Hospital North Haven Medical Center
North Haven, Connecticut · Recruiting
Smilow Cancer Hospital Care Center at Long Ridge
Stamford, Connecticut · Recruiting
Smilow Cancer Hospital-Torrington Care Center
Torrington, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut · Recruiting
Smilow Cancer Hospital-Waterbury Care Center
Waterbury, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
Emory Saint Joseph's Hospital
Atlanta, Georgia · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Northwestern Medicine Cancer Center Old Irving Park
Chicago, Illinois · Recruiting
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
Northwestern Medicine Oak Brook
Oak Brook, Illinois · Recruiting
Memorial Hospital East
Shiloh, Illinois · Recruiting
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois · Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Recruiting
University Medical Center New Orleans
New Orleans, Louisiana · Recruiting
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan · Recruiting
West Michigan Cancer Center
Kalamazoo, Michigan · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri · Recruiting
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Siteman Cancer Center-South County
St Louis, Missouri · Recruiting
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.